Publicacións en colaboración con investigadores/as de Gustave Roussy Cancer Campus (21)

2024

  1. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer

    Clinical Lung Cancer, Vol. 25, Núm. 3, pp. 233-243.e8

  2. Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 12, pp. 1350-1356

  3. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    Annals of Oncology, Vol. 35, Núm. 1, pp. 66-76

2023

  1. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

    The Lancet, Vol. 401, Núm. 10379, pp. 821-832

  2. Fibroblasts generate topographical cues that steer cancer cell migration

    Science advances, Vol. 9, Núm. 33, pp. eade2120

  3. Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges

    Nature Reviews Clinical Oncology, Vol. 20, Núm. 10, pp. 664-677

  4. MET alterations in NSCLC—Current Perspectives and Future Challenges

    Journal of Thoracic Oncology, Vol. 18, Núm. 4, pp. 419-435

  5. Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry

    JTO Clinical and Research Reports, Vol. 4, Núm. 1

  6. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

    Annals of Oncology, Vol. 34, Núm. 5, pp. 468-476

  7. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

    Annals of Oncology, Vol. 34, Núm. 10, pp. 920-933

  8. Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer

    Lung Cancer, Vol. 178, pp. 116-122

  9. Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial

    Targeted Oncology, Vol. 18, Núm. 5, pp. 639-641

2022

  1. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations

    European Journal of Cancer, Vol. 167, pp. 142-148

  2. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations

    European Journal of Cancer

2020

  1. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment

    Lung Cancer, Vol. 150, pp. 90-96

  2. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

    The Lancet Oncology, Vol. 21, Núm. 5, pp. 645-654

2019

  1. EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer

    European Journal of Cancer, Vol. 117, pp. 60-68

2018

  1. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: A Meta-analysis

    Journal of the National Cancer Institute, Vol. 110, Núm. 6, pp. 560-567

2017

  1. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

    European Journal of Cancer, Vol. 82, pp. 16-24

2011

  1. International distribution and age estimation of the Portuguese BRCA2 c.156-157insAlu founder mutation

    Breast Cancer Research and Treatment, Vol. 127, Núm. 3, pp. 671-679